Table 2. Main results for meta-analysis between negative E-cadherin expression and clinicopathological features.

Association between E-cadherin and clinical features	No. Reference Studies	Overall OR (95% CI)	Heterogeneity test (Q, I2, p)
Age (< 50 vs. ≥ 50)	Shim, H. S. [23], Huang, H. N. [18], Wang, Y. [27]	0.94 (0.56,1.65)	6.75, 70.4%, 0.83 (random-effected)
FIGO stage (I/II vs. III/IV)	Darai, E. [20], Faleiro Rodrigues, C. [13], Voutilainen, K. A. [21], Cho, E. Y. [22], Shim, H. S. [23], Dian, D. [24], Huang, H. N. [18], Wang, Y. [27], Yu, L. [29]	0.42 (0.31,0.57)	39.97, 80.0%, < 0.01 (random-effected)
Tumor grade (1/2 vs. 3)	Darai, E. [20], Faleiro Rodrigues C. [13], Voutilainen, K. A. [21], Cho, E. Y. [22], Shim, H. S. [23], Dian, D. [24], Bacic, B. [26], Wang, Y. [27]	0.48 (0.34,0.67)	9.17, 23.7%, < 0.01 (fixed-effected)
Histologic type (serous vs. others)	Darai, E. [20], Faleiro Rodrigues, C. [13], Voutilainen, K. A. [21], Yu, L. [29]	1.43 (0.93,2.19)	2.02, 0.0%, < 0.01 (fixed-effected)
Metastasis (Absent vs. Present)	Cho, E. Y. [22], Dian, D. [24], Wang, Y. [27], Yu, L. [29]	0.13 (0.07,0.26)	5.04, 40.5%, < 0.01 (fixed-effected)
Lymph node or vascular invasion (Absent vs. Present)	Faleiro Rodrigues, C. [13], Dian, D. [24], Bacic, B. [26], Huang, H. N. [18]	0.67 (0.36,1.24)	3.80, 21.0%, 0.20 (fixed-effected)
Recurrence (Absent vs. Present)	Darai, E. [20], Voutilainen, K. A. [21], Cho, E. Y. [22], Shim, H. S. [23]	0.48 (0.29,0.79)	1.25, 0.0%, < 0.01 (fixed-effected)